Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GLSI
GLSI logo

GLSI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Greenwich Lifesciences Inc (GLSI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
23.380
1 Day change
-2.54%
52 Week Range
34.100
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Greenwich Lifesciences Inc (GLSI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of significant positive catalysts, neutral trading sentiment, and absence of recent financial or valuation data make it prudent to hold off on investing in this stock right now. Additionally, technical indicators and trading signals do not suggest a compelling entry point.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 44.835, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support levels are at 21.383 and 20.3, while resistance levels are at 24.89 and 25.973. Overall, the technical indicators do not provide a strong buy signal.

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

  • The stock has shown a -2.54% regular market change and a -1.54% post-market change. Technical indicators suggest bearish momentum, and there is no recent news or financial data to support a positive outlook.

Financial Performance

No financial performance data available due to an error in retrieving the latest quarter's information.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast GLSI stock price to rise
2 Analyst Rating
Wall Street analysts forecast GLSI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 23.990
sliders
Low
45
Averages
47.5
High
50
Current: 23.990
sliders
Low
45
Averages
47.5
High
50
H.C. Wainwright
Buy
upgrade
$39 -> $50
AI Analysis
2025-12-30
Reason
H.C. Wainwright
Price Target
$39 -> $50
AI Analysis
2025-12-30
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Greenwich LifeSciences to $50 from $39 and keeps a Buy rating on the shares. The firm cites the positive efficacy in the non-HLA-A*02 arm of the ongoing Phase 3 FLAMINGO-01 trial of GLSI-100 in breast cancer for the target boost. GLSI-100 reduced breast cancer recurrence by 80% in the non- HLA-A*02 arm, the analyst tells investors in a research note. H.C. Wainwright views the preliminary data as "highly encouraging," saying it could double the market for GLSI-100.
Noble Capital
Outperform
initiated
$45
2025-08-20
Reason
Noble Capital
Price Target
$45
2025-08-20
initiated
Outperform
Reason
Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees \"large market potential\" for GLSI-100.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GLSI
Unlock Now

People Also Watch